| 000 | 01824 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250517154900.0 | ||
| 264 | 0 | _c20170918 | |
| 008 | 201709s 0 0 eng d | ||
| 022 | _a1872-7905 | ||
| 024 | 7 |
_a10.1016/j.jim.2017.05.008 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aWang, Zhaohui | |
| 245 | 0 | 0 |
_aOntak-like human IL-2 fusion toxin. _h[electronic resource] |
| 260 |
_bJournal of immunological methods _c09 2017 |
||
| 300 |
_a51-58 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xmetabolism |
| 650 | 0 | 4 | _aCell Line, Tumor |
| 650 | 0 | 4 |
_aDiphtheria Toxin _xpharmacology |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunoconjugates _xgenetics |
| 650 | 0 | 4 |
_aInterleukin-2 _xbiosynthesis |
| 650 | 0 | 4 |
_aInterleukin-2 Receptor alpha Subunit _ximmunology |
| 650 | 0 | 4 |
_aLymphoma, T-Cell, Cutaneous _xdrug therapy |
| 650 | 0 | 4 | _aMice, Inbred NOD |
| 650 | 0 | 4 | _aMice, Knockout |
| 650 | 0 | 4 | _aMice, SCID |
| 650 | 0 | 4 |
_aPichia _xgenetics |
| 650 | 0 | 4 |
_aRecombinant Fusion Proteins _xpharmacology |
| 650 | 0 | 4 | _aSafety-Based Drug Withdrawals |
| 650 | 0 | 4 |
_aSkin Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aTime Factors |
| 650 | 0 | 4 |
_aTumor Burden _xdrug effects |
| 650 | 0 | 4 | _aXenograft Model Antitumor Assays |
| 700 | 1 | _aZheng, Qian | |
| 700 | 1 | _aZhang, Huiping | |
| 700 | 1 | _aBronson, Roderick T | |
| 700 | 1 | _aMadsen, Joren C | |
| 700 | 1 | _aSachs, David H | |
| 700 | 1 | _aHuang, Christene A | |
| 700 | 1 | _aWang, Zhirui | |
| 773 | 0 |
_tJournal of immunological methods _gvol. 448 _gp. 51-58 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.jim.2017.05.008 _zAvailable from publisher's website |
| 999 |
_c27216597 _d27216597 |
||